A cost too high to bear? Prophylaxis versus preemptive therapy to prevent post-transplantation cytomegalovirus

Kidney International

Volumn 72, Issue 8, 2007, Pages 912-913

  Pescovitz, M D ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR;

CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG COST; GRAFT SURVIVAL; HEALTH CARE PERSONNEL; HUMAN; INFECTION PREVENTION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW;

EID: 34948911188     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002444     Document Type: Note

References (14)

1. Winston DJ, Winn D, Shaked A et al. Randomized comparison of ganciclovir and high-dose acyclovir to prevent cytomegalovirus for long-term cytomegalovirus prophylaxis in liver transplant recipients. Lancet 1995; 346: 43-50.
2. Gane E, Saliba F, Valdecasas GJ et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [published erratum appears in Lancet 1998; 351: 454]. Lancet 1997; 350: 1729-1733.
3. Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811-2815.
4. Pescovitz MD. Valganciclovir. Transplant Rev 2006; 20: 82-87.
5. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
6. Pescovitz MD. Valganciclovir: dosing strategies for effective CMV prevention. Trends Transplant 2007; 1: 35-43.
7. Doyle AM, Warburton KM, Goral S et al. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81: 1106-1111.
8. Dmitrienko S, Yu A, Balshaw R et al. Prediction, prognosis, and treatment costs for CMV infection in renal transplantation with consensus management guidelines. Kidney Int 2007; 72: 1014-1022.
9. Khoury JA, Storch GA, Bohl DL et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134-2143.
10. Andreoni KA, Brayman KL, Guidinger MK et al. Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant 2007; 7 (Suppl 1): 1359-1375.
11. Humar A, Paya C, Pescovitz MD et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 2004; 4: 644-649.
12. Sagedal S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850-856.
13. Kalil AC, Levitsky J, Lyden E et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870-880.
14. Cellular transport and function of human cytomegalovirus structural proteins. Radsak K. Institute für Virolgoie Robert-Knoch-Str. 17 35037 MARBURG/Germany. 〈http://www.med.unimarburg. de/stpg/ukm/lt/hygiene/viro/ radsak/cmv.jpeg〉 2007.